1 Establishment of an evaluation panel for the decentralized technical evaluation of the

2 sensitivity of 31 rapid detection tests for SARS-CoV-2 diagnostics

- 3 Andreas Puyskens^{a§}, Eva Krause^{a§}, Janine Michel^{a§}, Micha Nübling^b, Heinrich Scheiblauer^b,
- 4 Daniel Bourquain^a, Marica Grossegesse^a, Roman Valusenko^a, Viktor Corman^c, Christian
- 5 Drosten^c, Katrin Zwirglmaier^d, Roman Wölfel^d, Constanze Lange^e, Jan Kramer^e, Johannes
- 6 Friesen^f, Ralf Ignatius^f, Michael Müller^f, Jonas Schmidt-Chanasit^g, Petra Emmerich^g, Lars
- 7 Schaade^a, Andreas Nitsche^a*
- ^aRobert Koch Institute, Centre for Biological Threats and Special Pathogens Highly
- 9 Pathogenic Viruses (ZBS 1)
- ^bTesting Laboratory for In-vitro Diagnostic Medical Devices, Paul-Ehrlich-Institute, Paul-
- 11 Ehrlich-Straße 51-59, 63225 Langen, Germany
- ¹² ^cCharité Universitätsmedizin Berlin, Institute of Virology, Rahel-Hirsch-Weg 3, 10117 Berlin,
- 13 Germany
- ^dBundeswehr Institute of Microbiology, Neuherbergstraße 11, 80937 Munich, Germany
- ^eLADR Der Laborverbund Dr. Kramer & Kollegen GbR, Lauenburger Straße 67, 21502
- 16 Geesthacht, Germany
- ¹⁷ ^fMVZ Labor28 GmbH, Mecklenburgische Str. 28, 14197 Berlin
- 18 ^gBernhard Nocht Institute for Tropical Medicine, Arbovirology Department, Bernhard-Nocht-
- 19 Straße 74, 20359 Hamburg, Germany
- 20
- 21 [§] These authors contributed equally to this work
- 22
- 23 *Corresponding author
- 24 Prof. Dr. Andreas Nitsche

- 25 Robert Koch Institute
- 26 Centre for Biological Threats and Special Pathogens Highly Pathogenic Viruses
- 27 Seestraße 10
- 28 13353 Berlin, Germany
- 29 Phone: +49 30 187542313
- 30 E-Mail: NitscheA@rki.de
- 31

32 Abstract

33 Background

- 34 The detection of SARS-CoV-2 with rapid diagnostic tests has become an important tool to
- 35 identify infected people and break infection chains. These rapid diagnostic tests are usually
- 36 based on antigen detection in a lateral flow approach.

37 Aims & Methods

- 38 While for PCR diagnostics the validation of a PCR assay is well established, for antigen tests
- e.g. rapid diagnostic tests there is no common validation strategy. Here we present the
- 40 establishment of a panel of 50 pooled clinical specimens that cover a SARS-CoV-2

41 concentration range from approximately 1.1 x 10⁹ to 420 genome copies per mL of

42 specimen. The panel was used to evaluate 31 rapid diagnostic tests in up to 6 laboratories.

43 Results

- 44 Our results show that there is significant variation in the detection limits and the clinical
- 45 sensitivity of different rapid diagnostic tests. We conclude that the best rapid diagnostic
- tests can be applied to reliably identify infectious individuals who are presenting with SARS-
- 47 CoV-2 loads correlated to 10⁶ genome copies per mL of specimen. Infected individuals
- displaying SARS-CoV-2 genome loads corresponding to less than 10⁶ genome copies per mL
- 49 will be identified by only some rapid diagnostics tests, while many tests miss these viral
- 50 loads to a large extent.

51 Conclusions

- 52 Sensitive RDTs can be applied to identify infectious individuals with high viral loads, but not
- 53 to identify infected individuals.

54 Background

55	PCR-based diagnostics of SARS-CoV-2 is a well-established method with numerous
56	commercially available kits and in-house assays published over the last months [1]. Although
57	it is beyond question that in particular real-time PCR provides an unrivalled degree of
58	analytical sensitivity and reproducibility, there are some obvious limitations [2]. First of all,
59	PCR-based diagnostics requires a functioning laboratory infrastructure and skilled personnel.
60	The PCR reaction itself requires only about 2 hours, including pre- and post-analytical steps;
61	however, time to result in high-throughput mode is about 24 hours or more.
62	The need for faster and simpler approaches to diagnose a SARS-CoV-2 infection is therefore
63	evident as well as the need for on-site tests and for diagnostics in regions of lower standards
64	of laboratory infrastructure [3–5]. One promising technology is using lateral flow
65	immunoassays detecting SARS-CoV-2-specific proteins in respiratory secretions which
66	operate within less than 30 minutes (Rapid Diagnostic Test: RDT) [6]. The trade-off for a
67	simple and quick diagnostic test is an often significantly lower analytical sensitivity and
68	specificity compared to nucleic acid amplification techniques like PCR [7,8].
69	Beside the traditional RDTs whose read-out is performed visually, there are assays that
70	utilize readers for the identification of positive signals. These readers can provide a better
71	sensitivity, reproducibility and objectivity, in particular with fluorescence-based-formats;
72	however, the mobility and parallel testing of many specimens can be negatively affected.
73	Here we describe the decentralized evaluation of the sensitivity of 31 RDTs by up to six
74	German laboratories investigating an identical panel of 50 pools of clinical specimens. By this
75	approach, we generated at least two independent results per RDT and hence addressed

- inter-laboratory variations that have to be considered when RDTs are performed in different
- 77 locations by different persons.

78 Material & Methods

79 Evaluation panel

80	To enable the systematic and comparable decentralized evaluation of numerous RDTs, a
81	panel of 50 samples was compiled by pooling in total approximately 500 specimens which
82	had been collected between March and September 2020 (Panel 1V1). For this purpose, up to
83	ten respiratory specimens obtained for routine diagnostics with different virus loads were
84	pooled. Pools were frozen at -80 °C. Real-time PCR [(9)] was applied to determine the RNA
85	load per pool. In vitro RNA (provided by WHO) as well as the quantitative reference material
86	provided by INSTAND were used for quantification (https://www.instand-ev.de). Finally, the
87	panel covered a range of SARS-CoV-2 RNA from 1.1x10 ⁹ genomes per mL down to 420
88	genomes per mL. The study obtained ethical approval by the Berliner Ärztekammer (Berlin
89	Chamber of Physicians, Eth 20/40). When Panel 1V1 was used up, new pools were generated
90	by diluting the same samples as for Panel 1V1 (except for 4 pools 1–4 that had to be
91	constituted from new clinical specimens collected between October 2020 and January 2021),
92	resulting in comparable virus loads as determined by PCR, and the panel was labelled Panel
93	1V2. Panel 1V1 was compared to Panel 1V2 with RDT #3 and RDT #31 and showed identical
94	results. Panel 1V1 and Panel 1V2 have been extensively used to evaluate the sensitivity of
95	122 RDTs as described in the tandem publication by Scheiblauer et al.)

Previous studies revealed that a minimal RNA genome copy number of 10⁶ genome copies
per mL of specimen represents an amount of infectious virus particles which is required for
successful virus propagation in cell culture [9–12]. To correlate the pools to potential

infectivity by a specimen, we subjected the pools with $\geq 10^6$ genome copies per mL,

- 100 corresponding to a CT value <25, to cell culture. Confirmation of replication-competent
- 101 SARS-CoV-2 was achieved by inoculation of VeroE6 cells with the respective pools. Pools
- 102 containing infectious SARS-CoV-2 were subsequently titrated on VeroE6 cells. However, even
- 103 if pools containing higher amounts of SARS-CoV-2 RNA showed generally higher titres than
- 104 those with lower genome numbers, we observed no significant correlation between the
- 105 genome load and the titre (data not shown).
- 106 The specifications of the 50 pools are listed in table 1; pools allowing SARS-CoV-2
- 107 propagation are marked in bold.

108

109 Table 1: Characteristics of the 50 pools constituting Panel 1V1 and Panel 1V2.

Panel 1V1			Panel 1V2		
Pool-Nr.	CT/5 μL of RNA	RNA subjected to test	Pool-Nr.	CT/5 μL of RNA	RNA subjected to test
1	17.55	1.1E+07	1	17.31	1.31E+07
2	20.54	1.4E+06	2	19.08	3.87E+06
3	20.38	1.6E+06	3	19.62	2.67E+06
4	20.98	1.0E+06	4	20.61	1.35E+06
5	20.28	1.7E+06	5	20.60	1.36E+06
6	20.20	1.8E+06	6	21.21	8.96E+05
7	21.71	6.4E+05	7	22.15	4.70E+05

8	21.95	5.4E+05	8	22.32	4.18E+05
9	22.14	4.7E+05	9	23.13	2.39E+05
10	22.88	2.8E+05	10	23.21	2.27E+05
11	22.34	4.1E+05	11	23.13	2.27E+05
12	21.82	5.9E+05	12	22.12	4.79E+05
13	23.32	2.1E+05	13	25.29	5.42E+04
14	24.28	1.1E+05	14	24.97	6.76E+04
15	24.14	1.2E+05	15	24.38	1.01E+05
16	22.55	3.6E+05	16	22.88	2.84E+05
17	24.00	1.3E+05	17	24.81	7.54E+04
18	25.30	5.4E+04	18	28.33	6.71E+03
19	25.50	4.7E+04	19	25.45	2.39E+05
20	26.27	2.8E+04	20	29.46	2.27E+05
21	25.54	4.6E+04	21	25.95	2.27E+05
22	25.87	3.7E+04	22	27.42	4.79E+05
23	24.04	1.3E+05	23	24.45	5.42E+04
24	25.24	5.6E+04	24	25.20	6.76E+04
25	29.70	2.6E+03	25	25.07	1.01E+05
26	25.47	4.8E+04	26	26.32	2.84E+05
27	25.14	6.0E+04	27	26.12	7.54E+04
28	27.14	1.5E+04	28	27.41	6.71E+03
29	27.15	1.5E+04	29	27.34	1.33E+04
30	28.86	4.7E+03	30	27.24	1.42E+04

31	25.27	5.5E+04	31	26.24	1.42E+04
32	26.44	2.5E+04	32	26.64	2.14E+04
33	28.96	4.4E+03	33	28.92	4.47E+03
34	27.89	9.1E+03	34	27.82	9.53E+03
35	27.04	1.6E+04	35	26.66	2.12E+04
36	28.13	7.7E+03	36	27.05	1.62E+04
37	30.54	1.5E+03	37	30.13	1.95E+03
38	28.14	7.6E+03	38	29.36	3.31E+03
39	29.76	2.5E+03	39	30.12	1.96E+03
40	27.65	1.1E+04	40	28.19	7.39E+03
41	30.13	1.9E+03	41	30.14	7.39E+03
42	28.43	6.2E+03	42	29.48	3.04E+03
43	31.05	1.0E+03	43	31.61	7.04E+02
44	29.24	3.6E+03	44	29.51	2.98E+03
45	30.10	2.0E+03	45	31.19	9.40E+02
46	31.54	7.4E+02	46	31.34	8.48E+02
47	35.19	6.0E+01	47	34.55	9.34E+01
48	32.06	5.2E+02	48	31.19	9.40E+02
49	35.22	5.9E+01	49	36.04	3.35E+01
50	36.36	2.7E+01	50	35.83	3.87E+01

110 CT values given in bold indicate that SARS-CoV-2 could be propagated in cell culture.

111

113 **RDT selection**

- 114 RDTs included in this study were selected according to availability at the time of the study
- (table 2). No technical assumptions were made in the RDT selection process.

116

117 Table 2: RDTs evaluated in this study

#	Name	Manufacturer/distributer	# of evaluating laboratories
	Classical Point-of-Care tests		
1	SARS-CoV-2 Rapid Antigen Test	SD BIOSENSOR, distr. by Roche Diagnostics GmbH	6
2	Panbio™ COVID-19 Ag Rapid Test Device (Nasopharyngeal)	Abbott	5
3	RIDA® QUICK SARS-CoV-2 Antigen	R-Biopharm AG	3
4	Cleartest	servoprax GmbH	2
5	Dedicio COVID-19 Ag plus Test	Jiangsu Changfeng Medical Industry Co., Ltd., distr. by nal von minden GmbH	3
6	NADAL [®] COVID-19 Ag Test	nal von minden GmbH	3
7	BIOCREDIT COVID-19 Ag	RapiGEN Inc., distr. by Weko Pharma	3
8	STANDARD™ Q COVID-19 Ag Test	SD BIOSENSOR	2
9	BIOSYNEX COVID-19 Ag BSS	Biosynex Swiss SA	2

10	MEDsan [®] SARS-CoV-2 Antigen	MEDsan GmbH	2
	Rapid Test		

11	NowCheck [®] COVID-19 Ag Test	BIONOTE, distr. by concile	3
12	COVID-19 Rapid Ag Test Cassette	Zhejiang Orient Gene Biotech Co., Ltd	2
13	ESPLINE [®] SARS-CoV-2	Fujirebio Inc.	2
14	COVID-19 Ag Respi-Strip	Coris BioConcept	2
15	Healgen Coronavirus Ag Rapid Test Cassette (Swab)	Healgen Scientific LLC	2
16	Keul-o-test®	Günter Keul GmbH	2
17	Acro Rapid Test COVID-19 Antigen Rapid Test (Nasopharyngeal Swab)	Acro Biotech. Inc.	2
18	COVID-19 Antigen Schnelltest (Nasen-Rachenabstrich)	MEXACARE GmbH	2
19	COVID-19 Antigen Rapid Test Kit	Beijing Beier Bioengineering Co., Ltd.	2
20	mö-screen Testkit Corona Antigen Nasenabstrich	möLab GmbH	2
21	Medicovid SARS-CoV-2 AG Antigen Schnelltest	Xiamen Biotime Biotechnology Co., Ltd., distr. by MEDICE Arzneimittel Pütter GmbH & Co. KG	2
22	GENEDIA COVID-19 Ag	Green Cross Medical Science Corp.	2
23	COVID-19 Antigen Test Kit	Guangdong Wesail Biotech Co., Ltd., distr. by Bio-Gram Diagnostics GmbH	2
24	COVID-19 Antigen Schnelltest (Colloidal Gold)	Joinstar Biomedical Technology Co., Ltd., distr. by care impuls Vertriebs GmbH	2
25	blnk COVID-19 Antigen Rapid Test (Nasopharyngeal Swab)	Hangzhou Realy Tech Co. Ltd., distr. by TREKSTOR GmbH	2
26	Novel Coropovirus (COVID 19)	Hangzhou Laihe Biotech Co	2

	Antigen Test Kit	distr. by Lissner Qi GmbH	
27	COVID-19 Antigen Rapid Test Strip	Koch Biotechnology (Beijing) Co., Ltd.	2
	RDTs requiring a read-out device		
28*	STANDARD™ F COVID-19 Ag FIA	SD Biosensor	4
29*	Sofia SARS Antigen FIA	Quidel Corporation	3
30*	ScheBo® SARS-CoV-2 Quick™ Antigen	Schebo Biotech AG	3
31*	Wantai SARS-CoV-2 Antigen Rapid Test (FIA)	Beijing Wantai Biological Pharmacy	2

118 RDTs marked with * require a test-specific device and are not to be judged visually with the 119 device.

120

121

122 **RDT procedure**

123	In general, RDTs were used as recommended by the manufacturer's instructions. 50 μL of
124	each pool were either subjected to the RDT using all buffers in volumes as recommended by
125	the manufacturer, or the swab included in the RDT kit was used to absorb the 50 μL of each
126	pool and then subjected to the RDT procedure as recommended by the manufacturer.
127	Results obtained by visual examination of the test device by different laboratories were
128	categorized as "positive" or "negative" and subjected to statistical analysis by using the
129	GraphPad Prism software as indicated in the results section. Results were only accepted
130	when the control band was positive, which was the case in more than 99% of the tests run.

131 Results

132 **Evaluation panel establishment**

133	Prior to distribution of the panel we compared the detectability of specimens before and
134	after freezing at -40°C with two RDTs (#2, #3) and observed no significant differences in the
135	virus concentration range close to the detection limit (data not shown). Furthermore, to test
136	whether pooling and freezing had an impact on the detectability of specimens, we compared
137	up to 44 fresh clinical specimens, representing a CT value range from 20 to 35 (1.8x10 ⁷ to
138	7.0x10 ³ genome copies per mL), with the 32 pools of Panel 1V1 covering the same range
139	with in total 10 RDTs (#2, #3, #7, #8, #10, #11, #14, #21, #28, #31). In none of the RDTs
140	tested we observed a significant discrepancy between the detectability of fresh specimens
141	and pools with a similar CT value (data summarized in supplemental figure 1).
142	
143	Supplemental figure 1: Comparison of 10 randomly selected RDTs with pools from Panel 1V1
144	(n \leq 32) and fresh clinical specimens (n \leq 44), covering a genome load from approximately 10^7
145	to 7x10 ³ genome copies per mL. None of the RDTs showed a significant difference in the
146	detectability of pools in comparison to fresh specimens.
147	
148	RDT analytical sensitivity

The panel was shipped on dry ice to the participating laboratories. Prior to use, the panel was thawed, mixed and aliquoted, and identical aliquots were used immediately to allow maximum comparability between laboratories and test days. Figure 1 summarizes the workflow as recommended to the participating laboratories. Assessment of results was performed visually by experienced laboratory personnel.

154

Figure 1: Recommendation for panel usage to guarantee maximum comparability betweendifferent laboratories and points in time of validation.

157

158	Figure 2 comprises the results obtained for the sensitivity of 27 RDTs that could be analysed
159	visually (RDT #1–27) and the results for RDTs that needed a device for read-out (RDT #28–
160	31). Based on binary logistic regression of merged results obtained from different
161	laboratories, the 50% probability to detect a certain genome load was calculated as a marker
162	for the detection limit of an RDT. Six out of 31 RDTs showed a 50% detection probability for
163	genome loads higher than 10^6 genome copies per mL. Out of 31 RDTs, 24 had a 50%
164	detection probability of less than 10 ⁶ genome copies per mL, while 15 had a 50% detection
165	probability of less than 10^5 genome copies per mL. The most sensitive RDTs detected
166	approximately 75,000 genome copies per mL with a probability of 90%, while the least
167	sensitive RDT showed a 90% detection probability for 2.3 x 10 ⁷ genomes per mL.
168	Figure 2 also shows that using the RDT-specific swabs to absorb the pool material prior to
169	testing can lead to a loss of analytical sensitivity of approximately the factor 10 to 50,
170	although some of the RDTs showed only small differences between direct application of the
171	pool and swab usage. This indicates a varying efficiency of the absorption and release
172	characteristics for SARS-CoV-2 particles from the swabs.

173

Figure 2: Analytical sensitivity expressed by the 50% detection probability of 31 RDTs. RDTs
28 to 31 require an additional device for reading out the result. Binary logistic regression was

applied to calculate the analytical sensitivity from the 50 samples included in the panel.
Open blue bars represent the results when virus-containing pools were directly subjected to
the RDT without using a swab. Open green squares represent the corresponding results
when using a swab. Crossed squares indicate that no results were determined with swabs,
while green crosses show the one positive result from a pool with the corresponding virus
load to CT 17.55, pool #1.

182

183 **RDT clinical sensitivity**

184	To determine the clinic	al sensitivity of an RDT	, results of different la	boratories were merged
-----	-------------------------	--------------------------	---------------------------	------------------------

and categorized according to the genome load, e.g. CT value obtained for each pool by real-

time PCR [8a]: CT<25 (10⁶ genome copies per mL), 25<CT<30 and CT>30. Sensitivities of each

187 RDT to identify pools correctly were calculated for each CT category.

188 According to previous studies, CT<25 corresponds to an increased probability of a specimen

to successfully propagate SARS-CoV-2 in cell culture [9–11]. This was confirmed for 9/18

pools with CT values <25 for Panel 1V1 and 5/17 pools for Panel 1V2. Pools with a CT>30

191 were highly unlikely to contain virus amounts high enough to grow in cell culture. Specimens

192 with CT values between 25 and 30 very rarely propagated virus in cell culture.

193 Figure 3 summarizes the sensitivities for the 31 RDTs evaluated. Blue circles represent

194 results when no swab was used and green circles those when swabs were used. Figure 3A

shows the sensitivity for the whole number of 50 SARS-CoV-2-positive pools of the panel.

196 Results are further categorized according to the different virus loads represented by a pool.

197 Figure 3B covers pools with CT<25 (n=18 Panel 1V1, n=17 Panel 1V2, potentially infectious).

198 Figure 3C shows pools with CT>25 (n=32 Panel 1V1, n=33 Panel 1V2) and figure 3D pools

with a CT value between 25 and 30, which is the range where the RDTs showed significant
differences (n=23 for both panels). The number of laboratories contributing to a result is
given in table 1.

The data reveal that for virus loads higher than 10⁶ genome copies per mL (CT<25) the 202 203 sensitivity of 26/31 RDTs was higher than 80%, indicating that these RDTs would potentially 204 identify infectious specimens with a probability of 80% (figure 3A). For the latter RDTs, the 205 proficiency to detect these pools that contain culturable SARS-CoV-2 was even better with values up to 100% (data not shown). For a virus load $<10^{6}$ genome copies per mL (CT>25), 206 207 none of the evaluated tests could surpass a sensitivity of 80% (figure 3B). In the range 208 between CT 25 to CT 30, 10/31 RDTs reached a sensitivity of 80% and higher, even if five 209 further RDTs showed sensitivities close to 80% (figure 3D). Finally, when the sensitivity to 210 detect all 50 pools of the panel was determined, only 4/31 RDTs passed a sensitivity of 80% 211 or higher, with two of the four RDTs requiring a detection device for read-out. However, 212 10/31 RDTs showed an overall sensitivity higher than 70% (figure 3A). Using a swab to 213 reduce the volume of the pool material in the RDT test procedure can lead to reduced 214 sensitivity due to loss of virus particles in the absorption and release process. Hence, as 215 described for the analytical sensitivity based on the RNA detection limit, clinical sensitivities 216 were lower for most RDTs when a swab was used.

217

Figure 3: Clinical sensitivities of 31 RDTS as determined by two to six laboratories using 50
pools from evaluation Panels 1V1 and 1V2. Blue circles indicate direct application of the pool
to the test buffer and green circles indicate results using the RDT-specific swab. Each circle

- 221 represents the results of one laboratory (symbols may cover each other). RDTs 28 to 31
- 222 require an additional device for reading out the result.

223

- 224 Even if most of the RDTs were analysed in two independent laboratories only, RDTs 1–5 and
- 225 28–30 were evaluated 3–6 times with or without using swabs. As shown in figures 2 and 3,
- there can be significant variability for some tests, which is most likely due to the more
- subjective interpretation of a positive signal; however, most results were very similar even
- 228 when generated in different laboratories on different days.

229 Discussion

- 230 RDTs are promising tools in the diagnostic portfolio of tools for the identification of SARS-
- 231 CoV-2-infected individuals [13–15]. Since these tests do not use amplification of the target,
- like PCR, their analytical sensitivity is usually limited. Hence, the evaluation of RDTs plays a
- 233 major role in defining the proper applications of RDTs. In contrast to PCR, where the
- specimen can be inactivated, RDTs should be evaluated with clinical material that contains
- native viruses to mirror the diagnostic application as authentically as possible. However, the
- 236 systematic comparison of various RDTs in different laboratories at different times makes
- 237 larger sample volumes and a good storage stability necessary.
- 238 Multiple sampling of naso- and/or oropharyngeal swabs is hampered by reproducibility.
- 239 Even sampling the same patient with several swabs consecutively will likely lead to a
- variation in the virus load per swab which has to be controlled by real-time PCR, changing
- the test procedure. Because most of the RDT protocols require the clinical specimen to be
- sampled with a swab from which virus has to be eluted in the system-specific buffer, one

swab cannot be used more than once without changing the protocol. Therefore, the
decentralized evaluation of various RDTs in different laboratories is obviously difficult. So far,
clinical samples with semi-quantified SARS-CoV-2 concentrations or virus propagated in cell
culture have been used to validate RDTs [16–18]. This can be done for a limited number of
tests in a short period of time but is not suitable when numerous RDTs have to be compared
regularly in different laboratories.

Therefore, we established an evaluation panel that was used to determine the analytical and
clinical sensitivity of RDTs providing comparable results. The main basis of each pool were

251 dry swabs in PBS originally used for PCR diagnostics. Since some of the swabs were

transported to the laboratory in medium, the final concentration of medium in pools was

 $\leq 20\%$ for each pool, $\leq 10\%$ for 38 pools and 0% for 25 pools. Ten RDTs were randomly

selected to calculate whether the medium content had an impact on the sensitivity. As

shown in supplemental figure 2 for one of the RDTs, binary logistic regression revealed no

256 difference in the detection probability of pools containing varying amounts of medium.

257 Although these results are only derived from ten RDTs, we believe that this low medium

content has no influence on the test sensitivity in general, since pools with medium

percentages between 10% and 20% were distributed over the whole panel 1V1.

260

261 Supplemental figure 2: Impact of medium contents in the 50 pools included in Panel 1V1.

262 Binary logistic regression was used to demonstrate that the amount of medium ranging from

263 0% to 20% has no impact on the detection limit of one randomly selected RDT.

264

265	SARS-CoV-2 genome load was determined by real-time PCR in clinical specimens, and those
266	specimens with similar load were pooled diluted in a background of negative swabs and the
267	virus load quantified again. The established pools had a volume of 10 mL for both panel 1V1
268	and 1V2 and covered a genome load from 1.1x10 ⁹ genomes per mL down to 400 genomes
269	per mL, which is the range of typical clinical specimens analysed in our laboratory. Even if
270	the genome load does not reflect the number of virus particles directly, the RNA copy
271	number was recently used to estimate the number of virus particles reflecting the infectious
272	potential of a specimen and can correlate with the N protein concentration in clinical
273	samples [19].
274	The fact that we used pools of up to 10 clinical specimens facilitates to compensate to some
275	degree for a potential variation between individual samples, for example varying ratios of
276	genome copies to the number of viral particles or rather the antigen concentration.
277	We could demonstrate that the pools of the panel showed results comparable to those for
278	fresh clinical specimens with similar SARS-CoV-2 genome load when selected RDTs were
279	used, and that freezing at -40 to -80°C did not impact the detectability significantly.
280	Nevertheless, as a trade-off for better reproducibility and comparability, the material used
281	was not as fresh as in a clinical setting [.
282	Usually, RDTs use swabs that are subjected to the RDT-specific buffer before incubation of
283	the test membrane is done. Our approach necessarily began with liquid specimens of 50 μL ,
284	which is intended for some RDTs, but not for all of them. However, with the intention to
285	allow the generation of comparable and reproducible data, we accepted that some of the
286	buffers were diluted by the fluid of the pools. Adding 50 μl of pools directly to three

randomly selected RDTs without additional test-specific buffer led to results indicating that

- additional buffers were not required at least in these RDTs.
- 289 The strategy of using liquid specimens comes with a further benefit, e.g. the option to
- 290 cultivate the pools in cell culture, showing the infectivity of pools with a sufficient virus load.
- 291 To our knowledge, this is one of the few studies that systematically evaluated several
- 292 commercially available Ag RDTs using standardized samples in comparison to qPCR as well as
- infectivity data from cell culture [21]. However, since all specimens included in a pool have
- been frozen and thawed at least once, the capability to grow in cell culture can be improved
- with fresh clinical specimens of a comparable virus amount [22].
- 296 Variability observed in different laboratories has been described for diseases like malaria
- 297 [23] and was significant for some RDTs, but in general highly comparable results were
- 298 obtained. Therefore, our results reflect the natural variance that can be expected when
- 299 different users apply the RDTs. Over time we observed that users adopted the test and that
- 300 the differentiation of weak positive results from negative results became better with
- 301 increasing experience. Therefore, it can be assumed that the interpretation of results is
- better standardized with RDTs that require a device to read out the signal. Based on the
- 303 number of RDTs we have validated, we can confirm that read-out devices can help generate
- 304 better reproducible results and reduce the inter-user variance.
- 305 Influence of swabs on the sensitivity of RDTs

The common RDT test starts with the sampling that results in a swab containing material from the mucosa of the naso- or oropharynx. Then the swab is put into the RDT-specific buffer and is subjected to the test membrane. Applying liquid evaluation specimens with known virus amounts therefore does not consider the impact of the swab on the result. The

310 swab has to absorb liquids from the mucosa potentially containing SARS-CoV-2 or can scrape 311 cellular material containing virus; probably it is a combination of both. Beside the problem 312 that the swab does not quantitatively absorb the specimen, virus proteins can stick to the 313 swab and will not be subjected to the RDT, reducing the analytical sensitivity. While some of 314 the RDTs do not suffer significantly from using a swab prior to testing (#13, #28, #30), most of the tests lose sensitivity approximately by the factor 10 to 20. This does not mean that the 315 316 respective test device is inferior to the previously mentioned tests, but rather that the swab 317 is not efficient in absorbing and releasing SARS-CoV-2 from a liquid specimen. However, speculating that these swabs will come with the same drawbacks when used in clinical 318 sampling, the loss of sensitivity can also occur. In a patient carrying for example 10⁶ genome 319 320 copies in the nasopharynx, with RNA load used as surrogate for viral particles, the sampling 321 on the mucosa bears the risk to obtain a false negative result in the RDT due to considerable 322 loss of antigen in the swab. Further investigations of the efficiency of virus absorption and 323 release from a swab will help interpret the risk of false negatives by sampling. Besides, 324 further specimens like saliva are under investigation for their use in RDTs. Finally, our study did not address the specificity of an RDT and cannot assess the risk of false 325 326 positive results. However, recent studies show that high specificity is reached by most of the 327 RDTs evaluated [24]. In addition to SARS-CoV-2-positive specimens, the next version of the 328 evaluation panel will also include specimens containing SARS-CoV-2-negative specimens 329 positive for further respiratory viruses.

330 Conclusion

The sensitivity of the 31 RDTs evaluated in this study varied significantly and depended
largely on the virus load in the respective specimen. While four RDTs showed a sensitivity of

333	>80% over the whole range of virus loads investigated, 26 RDTs had a sensitivity of >80% for
334	potentially infectious specimens, indicating that sensitive RDTs can be used to identify
335	contagious individuals in various settings, but not to identify infected individuals with lower
336	virus loads. Our results are in agreement with several other studies not using a standardized
337	evaluation panel [25], indicating the applicability of the described panel for RDT evaluation.
338	The minimal performance characteristics for an RDT have been recently discussed to be at
339	least 80% for symptomatic patients [13]. Considering varying virus loads during the time
340	course of infection in an individual and in between individuals, the sensitivity of an RDT
341	should therefore better be attributed to a certain virus load instead of the time after onset
342	of symptoms or a qualitative PCR result.

343 Acknowledgements

- 344 The authors are grateful to Ursula Erikli for copy-editing. This work was funded by the
- 345 Ministry of Health, Germany (Maßnahmepaket 1&2).

346 Authors contributions

- 347 Andreas Puyskens, Eva Krause, Janine Michel and Marica Grossegesse designed the study,
- 348 established the evaluation panel and performed the RDTs with Roman Valusenko. Daniel
- 349 Bourquain performed cell culture experiments. Micha Nübling and Heinrich Scheiblauer
- 350 characterized the panel and evaluated several RDTs. Viktor Corman, Christian Drosten, Katrin
- 351 Zwirglmaier, Roman Wölfel, Constanze Lange, Jan Kramer, Johannes Friesen, Ralf Ignatius,
- 352 Michael Müller, Jonas Schmidt-Chanasit, and Petra Emmerich provided data for varying
- 353 numbers of RDTs with the evaluation panel. Lars Schaade and Andreas Nitsche
- 354 conceptualized the study, analysed the data and wrote the manuscript.

355 References

356	1.	Nalla AK, Casto AM, Huang M-LW, Perchetti GA, Sampoleo R, Shrestha L, et al.
357		Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different
358		Primer/Probe Sets and One Assay Kit. J Clin Microbiol. 2020;58(6).
359	2.	Mackay IM, Arden KE, Nitsche A. Real-time Fluorescent PCR Techniques to Study
360		Microbial-Host Interactions. Vol. 34, Methods in Microbiology. 2004. p. 255–330.
361	3.	Peeling RW, McNerney R. Emerging technologies in point-of-care molecular
362		diagnostics for resource-limited settings. Vol. 14, Expert Review of Molecular
363		Diagnostics. Expert Reviews Ltd.; 2014. p. 525–34.
364	4.	Strömer A, Rose R, Schäfer M, Schön F, Vollersen A, Lorentz T, et al. Performance of a
365		Point-of-Care Test for the Rapid Detection of SARS-CoV-2 Antigen. Microorganisms
366		[Internet]. 2020 Dec 28 [cited 2021 Apr 23];9(1):1–11. Available from:
367		http://www.ncbi.nlm.nih.gov/pubmed/33379279
368	5.	Jacobs J, Kühne V, Lunguya O, Affolabi D, Hardy L, Vandenberg O. Implementing
369		COVID-19 (SARS-CoV-2) Rapid Diagnostic Tests in Sub-Saharan Africa: A Review. Vol.
370		7:557797, Frontiers in Medicine. Frontiers Media S.A.; 2020. p. 557.
371	6.	Kozel TR, Burnham-Marusich AR. Point-of-care testing for infectious diseases: Past,
372		present, and future. Vol. 55, Journal of Clinical Microbiology. American Society for
373		Microbiology; 2017. p. 2313–20.
374	7.	Berzosa P, De Lucio A, Romay-Barja M, Herrador Z, González V, García L, et al.
375		Comparison of three diagnostic methods (microscopy, RDT, and PCR) for the detection
376		of malaria parasites in representative samples from Equatorial Guinea 11 Medical and

- 377 Health Sciences 1108 Medical Microbiology. Malar J [Internet]. 2018 Sep 17 [cited
- 378 2021 Apr 23];17(1):333. Available from:
- 379 https://malariajournal.biomedcentral.com/articles/10.1186/s12936-018-2481-4
- 8. Https://www.finddx.org/sarscov2-eval-antigen/. A from: FIND evaluation of SARS-
- 381 CoV-2 antigen (Ag) detecting tests FIND.
- 382 9. Janine Michel, Markus Neumann, Eva Krause, Thomas Rinner, Therese Muzeniek,
- 383 Marica Grossegesse, Georg Hille, Franziska Schwarz, Andreas Puyskens, Sophie
- 384 Förster, Barbara Biere, Daniel Bourquain, Cristina Domingo, Annika Brinkmann, Lars
- 385 Schaade, Livia Schr AN. Resource-efficient internally controlled in-house real-time PCR
- detection of SARS-CoV-2. Virol J. 2021;Forthcomin.
- 387 10. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.
- 388 Virological assessment of hospitalized patients with COVID-2019. Nature. 2020
- 389 May;581(7809):465–9.
- 390 11. Kim M-C, Cui C, Shin K-R, Bae J-Y, Kweon O-J, Lee M-K, et al. Duration of Culturable
- 391 SARS-CoV-2 in Hospitalized Patients with Covid-19. N Engl J Med. 2021;348(7):671–3.
- 392 12. van Kampen JJA, van de Vijver DAMC, Fraaij PLA, Haagmans BL, Lamers MM, Okba N,
- 393 et al. Duration and key determinants of infectious virus shedding in hospitalized
- 394 patients with coronavirus disease-2019 (COVID-19). Nat Commun. 2021 Dec
- 395 1;12(1):267.
- La Scola B, Le Bideau M, Andreani J, Hoang VT, Grimaldier C, Colson P, et al. Viral RNA
 load as determined by cell culture as a management tool for discharge of SARS-CoV-2
 patients from infectious disease wards. Eur J Clin Microbiol Infect Dis. 2020;

399	14.	WHO. COVID-19 Target product profiles for priority diagnostics to support response to
400		the COVID-19 pandemic v.1.0 [Internet]. 2020 [cited 2021 Apr 22]. Available from:
401		https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-
402		priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1
403	15.	Berger A, Nsoga MTN, Perez-Rodriguez FJ, Aad YA, Sattonnet-Roche P, Gayet-Ageron
404		A, et al. Diagnostic accuracy of two commercial SARSCoV- 2 antigen-detecting rapid
405		tests at the point of care in community-based testing centers. PLoS One. 2021 Mar
406		1;16(3 March 2021).
407	16.	Mboumba Bouassa RS, Veyer D, Péré H, Bélec L. Analytical performances of the point-
408		of-care SIENNA TM COVID-19 Antigen Rapid Test for the detection of SARS-CoV-2
409		nucleocapsid protein in nasopharyngeal swabs: A prospective evaluation during the
410		COVID-19 second wave in France. Int J Infect Dis. 2021 May 1;106:8–12.
411	17.	Olearo F, Nörz D, Heinrich F, Sutter JP, Roedel K, Schultze A, et al. Handling and
412		accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-
413		qPCR. J Clin Virol. 2021 Apr 1;137(April104782).
414	18.	Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, et al.
415		Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a
416		single-centre laboratory evaluation study. The Lancet Microbe. 2021 Apr;
417	19.	Jääskeläinen AE, Ahava MJ, Jokela P, Szirovicza L, Pohjala S, Vapalahti O, et al.
418		Evaluation of three rapid lateral flow antigen detection tests for the diagnosis of SARS-
419		CoV-2 infection. J Clin Virol. 2021 Apr 1;137.
420	20.	Pollock NR, Savage TJ, Wardell H, Lee R, Mathew A, Stengelin M, et al. Correlation of

- 421 SARS-CoV-2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples
- 422 from children and adults using an ultrasensitive and quantitative antigen assay.
- 423 medRxiv. medRxiv; 2020. p. 2020.11.10.20227371.
- 424 21. Kohmer N, Toptan T, Pallas C, Karaca O, Pfeiffer A, Westhaus S, et al. The Comparative
- 425 Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to
- 426 Infectivity In Vitro. J Clin Med. 2021 Jan 17;10(2):328.
- 427 22. Basile K, McPhie K, Carter I, Alderson S, Rahman H, Donovan L, et al. Cell-based
- 428 culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during
- 429 COVID-19. Clin Infect Dis. 2020 Oct 24;
- 430 23. Boyce MR, Menya D, Turner EL, Laktabai J, Prudhomme-O'Meara W. Evaluation of
- 431 malaria rapid diagnostic test (RDT) use by community health workers: A longitudinal
 432 study in western Kenya. Malar J. 2018 May 18;17(1).
- 433 24. Baro B, Rodo P, Ouchi D, Bordoy AE, Saya Amaro EN, Salsench S V., et al. Performance
- 434 characteristics of five antigen-detecting rapid diagnostic test (Ag-RDT) for SARS-CoV-2
- 435 asymptomatic infection: a head-to-head benchmark comparison. J Infect [Internet].
- 436 2021 Apr [cited 2021 Apr 23]; Available from:
- 437 https://linkinghub.elsevier.com/retrieve/pii/S0163445321001912
- 438 25. Dinnes J, Deeks JJ, Adriano A, Berhane S, Davenport C, Dittrich S, et al. Rapid, point-of-
- 439 care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection.
- 440 Cochrane Database Syst Rev. 2020 Aug 26;2020(8).

Figure 1



Created with BioRender.com

Figure 2



Figure 3

